Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas

S. Huang, U. D. Lichtenauer, S. Pack, C. Wang, A. C. Kim, M. Lutchman, C. A. Koch, J. Torres-Cruz, S. C. Huang, E. J. Benz, H. Christiansen, B. Dockhorn-Dworniczak, C. Poremba, Alexander Vortmeyer, A. H. Chishti, Z. Zhuang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objectives: EPB4.1 has been previously mapped to human chromosome 1p33-p34.2. In contradiction to this chromosomal location, we have mapped EPB4.1-1p36 by using fluorescence in situ hybridization and radiation hybrid mapping. In neuroblastomas, deletions of the telomeric end of chromosome 1 (1p36) are the most common genetic aberration. Methods: We investigated whether genetic aberrations of EPB4.1 can be detected in some neuroblastomas by analyzing 72 tumours for EPB4.1 mutation, expression, and alternative splicing pattern. Furthermore, EPB4.1 protein from a neuroblastoma cell line was studied for its subcellular localization. Results: Sequence changes could be detected in 14 out of 72 neuroblastomas, including missense, silent, and intronic changes. Duplex RT-PCR analysis revealed a subset of 11 tumours expressing significantly low levels of EPB4.1. Significant EPB4.1 sequence changes that were detected included an exon 4 G/A missense mutation (amino acid: V/I) that was shown to be associated with absence of wild-type EPB4.1 expression (3 tumours), an exon 8 G/A missense mutation (V/M) (1 tumour), and an intronic sequence change that was shown to be associated with the presence of an aberrant transcript (1 tumour). Splicing pattern analysis revealed that all EPB4.1 transcripts from tumours exclude exon 3, a splicing pattern for generating the 135 kDa isoform. EPB4.1 cDNA cloned from a neuroblastoma cell line produced a 135-kDa protein with a cytoplasm/membrane localization. Conclusions: Out of 72 neuroblastomas we have identified 11 tumours with impaired EPB4.1 expression and 5 tumours with significant sequence changes. We also found that the 135 kDa isoform is the main EPB4.1 product in neuroblastoma. EPB4.1 cDNA from a neuroblastoma cell line produced a 135-kDa protein and displayed a cytoplasm/membrane localization in transfected cells.

Original languageEnglish (US)
Pages (from-to)907-914
Number of pages8
JournalEuropean Journal of Clinical Investigation
Volume31
Issue number10
DOIs
StatePublished - Dec 1 2001
Externally publishedYes

Fingerprint

Neuroblastoma
Tumors
Genes
Neoplasms
Exons
Cells
Missense Mutation
Chromosomes
Aberrations
Cell Line
Protein Isoforms
Cytoplasm
Complementary DNA
Radiation Hybrid Mapping
Membranes
Proteins
Chromosomes, Human, Pair 1
Alternative Splicing
Human Chromosomes
Fluorescence In Situ Hybridization

Keywords

  • EPB4.1
  • In vitro transcription translation
  • Mutation analysis
  • Neuroblastoma
  • RT-PCR
  • SSCP

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Clinical Biochemistry

Cite this

Huang, S., Lichtenauer, U. D., Pack, S., Wang, C., Kim, A. C., Lutchman, M., ... Zhuang, Z. (2001). Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. European Journal of Clinical Investigation, 31(10), 907-914. https://doi.org/10.1046/j.1365-2362.2001.00892.x

Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. / Huang, S.; Lichtenauer, U. D.; Pack, S.; Wang, C.; Kim, A. C.; Lutchman, M.; Koch, C. A.; Torres-Cruz, J.; Huang, S. C.; Benz, E. J.; Christiansen, H.; Dockhorn-Dworniczak, B.; Poremba, C.; Vortmeyer, Alexander; Chishti, A. H.; Zhuang, Z.

In: European Journal of Clinical Investigation, Vol. 31, No. 10, 01.12.2001, p. 907-914.

Research output: Contribution to journalArticle

Huang, S, Lichtenauer, UD, Pack, S, Wang, C, Kim, AC, Lutchman, M, Koch, CA, Torres-Cruz, J, Huang, SC, Benz, EJ, Christiansen, H, Dockhorn-Dworniczak, B, Poremba, C, Vortmeyer, A, Chishti, AH & Zhuang, Z 2001, 'Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas', European Journal of Clinical Investigation, vol. 31, no. 10, pp. 907-914. https://doi.org/10.1046/j.1365-2362.2001.00892.x
Huang, S. ; Lichtenauer, U. D. ; Pack, S. ; Wang, C. ; Kim, A. C. ; Lutchman, M. ; Koch, C. A. ; Torres-Cruz, J. ; Huang, S. C. ; Benz, E. J. ; Christiansen, H. ; Dockhorn-Dworniczak, B. ; Poremba, C. ; Vortmeyer, Alexander ; Chishti, A. H. ; Zhuang, Z. / Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. In: European Journal of Clinical Investigation. 2001 ; Vol. 31, No. 10. pp. 907-914.
@article{31b74bec999547768dfb74dbeb27b510,
title = "Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas",
abstract = "Objectives: EPB4.1 has been previously mapped to human chromosome 1p33-p34.2. In contradiction to this chromosomal location, we have mapped EPB4.1-1p36 by using fluorescence in situ hybridization and radiation hybrid mapping. In neuroblastomas, deletions of the telomeric end of chromosome 1 (1p36) are the most common genetic aberration. Methods: We investigated whether genetic aberrations of EPB4.1 can be detected in some neuroblastomas by analyzing 72 tumours for EPB4.1 mutation, expression, and alternative splicing pattern. Furthermore, EPB4.1 protein from a neuroblastoma cell line was studied for its subcellular localization. Results: Sequence changes could be detected in 14 out of 72 neuroblastomas, including missense, silent, and intronic changes. Duplex RT-PCR analysis revealed a subset of 11 tumours expressing significantly low levels of EPB4.1. Significant EPB4.1 sequence changes that were detected included an exon 4 G/A missense mutation (amino acid: V/I) that was shown to be associated with absence of wild-type EPB4.1 expression (3 tumours), an exon 8 G/A missense mutation (V/M) (1 tumour), and an intronic sequence change that was shown to be associated with the presence of an aberrant transcript (1 tumour). Splicing pattern analysis revealed that all EPB4.1 transcripts from tumours exclude exon 3, a splicing pattern for generating the 135 kDa isoform. EPB4.1 cDNA cloned from a neuroblastoma cell line produced a 135-kDa protein with a cytoplasm/membrane localization. Conclusions: Out of 72 neuroblastomas we have identified 11 tumours with impaired EPB4.1 expression and 5 tumours with significant sequence changes. We also found that the 135 kDa isoform is the main EPB4.1 product in neuroblastoma. EPB4.1 cDNA from a neuroblastoma cell line produced a 135-kDa protein and displayed a cytoplasm/membrane localization in transfected cells.",
keywords = "EPB4.1, In vitro transcription translation, Mutation analysis, Neuroblastoma, RT-PCR, SSCP",
author = "S. Huang and Lichtenauer, {U. D.} and S. Pack and C. Wang and Kim, {A. C.} and M. Lutchman and Koch, {C. A.} and J. Torres-Cruz and Huang, {S. C.} and Benz, {E. J.} and H. Christiansen and B. Dockhorn-Dworniczak and C. Poremba and Alexander Vortmeyer and Chishti, {A. H.} and Z. Zhuang",
year = "2001",
month = "12",
day = "1",
doi = "10.1046/j.1365-2362.2001.00892.x",
language = "English (US)",
volume = "31",
pages = "907--914",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas

AU - Huang, S.

AU - Lichtenauer, U. D.

AU - Pack, S.

AU - Wang, C.

AU - Kim, A. C.

AU - Lutchman, M.

AU - Koch, C. A.

AU - Torres-Cruz, J.

AU - Huang, S. C.

AU - Benz, E. J.

AU - Christiansen, H.

AU - Dockhorn-Dworniczak, B.

AU - Poremba, C.

AU - Vortmeyer, Alexander

AU - Chishti, A. H.

AU - Zhuang, Z.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Objectives: EPB4.1 has been previously mapped to human chromosome 1p33-p34.2. In contradiction to this chromosomal location, we have mapped EPB4.1-1p36 by using fluorescence in situ hybridization and radiation hybrid mapping. In neuroblastomas, deletions of the telomeric end of chromosome 1 (1p36) are the most common genetic aberration. Methods: We investigated whether genetic aberrations of EPB4.1 can be detected in some neuroblastomas by analyzing 72 tumours for EPB4.1 mutation, expression, and alternative splicing pattern. Furthermore, EPB4.1 protein from a neuroblastoma cell line was studied for its subcellular localization. Results: Sequence changes could be detected in 14 out of 72 neuroblastomas, including missense, silent, and intronic changes. Duplex RT-PCR analysis revealed a subset of 11 tumours expressing significantly low levels of EPB4.1. Significant EPB4.1 sequence changes that were detected included an exon 4 G/A missense mutation (amino acid: V/I) that was shown to be associated with absence of wild-type EPB4.1 expression (3 tumours), an exon 8 G/A missense mutation (V/M) (1 tumour), and an intronic sequence change that was shown to be associated with the presence of an aberrant transcript (1 tumour). Splicing pattern analysis revealed that all EPB4.1 transcripts from tumours exclude exon 3, a splicing pattern for generating the 135 kDa isoform. EPB4.1 cDNA cloned from a neuroblastoma cell line produced a 135-kDa protein with a cytoplasm/membrane localization. Conclusions: Out of 72 neuroblastomas we have identified 11 tumours with impaired EPB4.1 expression and 5 tumours with significant sequence changes. We also found that the 135 kDa isoform is the main EPB4.1 product in neuroblastoma. EPB4.1 cDNA from a neuroblastoma cell line produced a 135-kDa protein and displayed a cytoplasm/membrane localization in transfected cells.

AB - Objectives: EPB4.1 has been previously mapped to human chromosome 1p33-p34.2. In contradiction to this chromosomal location, we have mapped EPB4.1-1p36 by using fluorescence in situ hybridization and radiation hybrid mapping. In neuroblastomas, deletions of the telomeric end of chromosome 1 (1p36) are the most common genetic aberration. Methods: We investigated whether genetic aberrations of EPB4.1 can be detected in some neuroblastomas by analyzing 72 tumours for EPB4.1 mutation, expression, and alternative splicing pattern. Furthermore, EPB4.1 protein from a neuroblastoma cell line was studied for its subcellular localization. Results: Sequence changes could be detected in 14 out of 72 neuroblastomas, including missense, silent, and intronic changes. Duplex RT-PCR analysis revealed a subset of 11 tumours expressing significantly low levels of EPB4.1. Significant EPB4.1 sequence changes that were detected included an exon 4 G/A missense mutation (amino acid: V/I) that was shown to be associated with absence of wild-type EPB4.1 expression (3 tumours), an exon 8 G/A missense mutation (V/M) (1 tumour), and an intronic sequence change that was shown to be associated with the presence of an aberrant transcript (1 tumour). Splicing pattern analysis revealed that all EPB4.1 transcripts from tumours exclude exon 3, a splicing pattern for generating the 135 kDa isoform. EPB4.1 cDNA cloned from a neuroblastoma cell line produced a 135-kDa protein with a cytoplasm/membrane localization. Conclusions: Out of 72 neuroblastomas we have identified 11 tumours with impaired EPB4.1 expression and 5 tumours with significant sequence changes. We also found that the 135 kDa isoform is the main EPB4.1 product in neuroblastoma. EPB4.1 cDNA from a neuroblastoma cell line produced a 135-kDa protein and displayed a cytoplasm/membrane localization in transfected cells.

KW - EPB4.1

KW - In vitro transcription translation

KW - Mutation analysis

KW - Neuroblastoma

KW - RT-PCR

KW - SSCP

UR - http://www.scopus.com/inward/record.url?scp=0035740056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035740056&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2362.2001.00892.x

DO - 10.1046/j.1365-2362.2001.00892.x

M3 - Article

VL - 31

SP - 907

EP - 914

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 10

ER -